Organon & Co Ordinary Shares OGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OGN is a good fit for your portfolio.
News
-
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
-
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
-
Organon Announces Proposed $1.0 Billion Senior Notes Offering
-
Organon Reports Results for the First Quarter Ended March 31, 2024
-
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
-
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
-
11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria
-
Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.
Trading Information
- Previous Close Price
- $20.31
- Day Range
- $19.94–20.31
- 52-Week Range
- $10.84–24.08
- Bid/Ask
- $20.12 / $20.99
- Market Cap
- $5.17 Bil
- Volume/Avg
- 1.9 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- 4.99
- Price/Sales
- 0.82
- Dividend Yield (Trailing)
- 5.51%
- Dividend Yield (Forward)
- 5.51%
- Total Yield
- 5.51%
Company Profile
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Value
- Total Number of Employees
- 10,000
- Website
- https://www.organon.com
Comparables
Valuation
|
Metric
|
OGN
|
OPCH
|
LDDD
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.99 | 25.36 | 154.06 |
Price/Book Value | 108.26 | 3.28 | 401.06 |
Price/Sales | 0.82 | 1.09 | 18.20 |
Price/Cash Flow | 5.34 | 12.13 | 63.94 |
Price/Earnings
OGN
OPCH
LDDD
Financial Strength
|
Metric
|
OGN
|
OPCH
|
LDDD
|
|---|---|---|---|
Quick Ratio | 0.83 | 1.25 | 0.94 |
Current Ratio | 1.65 | 1.77 | 1.04 |
Interest Coverage | 2.28 | 8.14 | — |
Quick Ratio
OGN
OPCH
LDDD
Profitability
|
Metric
|
OGN
|
OPCH
|
LDDD
|
|---|---|---|---|
Return on Assets (Normalized) | 9.70% | 9.23% | 106.04% |
Return on Equity (Normalized) | — | 20.96% | — |
Return on Invested Capital (Normalized) | 18.19% | 13.01% | — |
Return on Assets
OGN
OPCH
LDDD
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Vhydvztsj | Dpjkv | $808.7 Bil | |||
| Johnson & Johnson
JNJ
| Vlqbmwwqm | Lfhg | $350.6 Bil | |||
| Merck & Co Inc
MRK
| Xzykmqh | Jpcvz | $318.8 Bil | |||
| AbbVie Inc
ABBV
| Lmslxfjmm | Lvjh | $289.3 Bil | |||
| AstraZeneca PLC ADR
AZN
| Fbszytbhk | Pxkpw | $239.2 Bil | |||
| Novartis AG ADR
NVS
| Qjbscgg | Wksfs | $220.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Hbzcjjlsk | Tmltf | $218.3 Bil | |||
| Amgen Inc
AMGN
| Zlkngsnlx | Zlb | $166.0 Bil | |||
| Pfizer Inc
PFE
| Vdlvlhp | Fxws | $157.0 Bil | |||
| Sanofi SA ADR
SNY
| Vkkfflrk | Qddy | $122.8 Bil |